Select your Market
Financial results of Q3 2023
Forecast
| Q3 2023 (in € billion) | Change (in %, compared to Q3 2022) | Organic growth (in %, compared to Q3 2022) | |
|---|---|---|---|
| Group net sales | 5.2 | -10.9 | -4.1 |
| EBITDA pre | 1.4 | ‑20.2 | ‑13.2 |
| Life Science sales | 2.2 | -18.3 | -13.2 |
| Healthcare sales | 2.1 | -1.1 | 7.4 |
| Electronics sales | 0.9 | ‑11.6 | ‑4.0 |
We remain disciplined and on track to achieve not only our fiscal 2023 but also our medium-term targets. In 2024, we expect to return to organic sales growth.
Our CFO Helene von Roeder comments on the Q3 2023 results.
Detailed information about the development of our business in the third quarter of 2023.
Downloads for the Media
Additional Downloads
Press Releases
In the third quarter of 2023, Merck KGaA, Darmstadt, Germany, once again benefited from its diversified set-up.
2023/11/09
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
Media Relations
Head of Investor Relations
+49 6151 72 91-5271
